• 1. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 2. An ionic liquid promoted microwave-hydrothermal route towards highly photoluminescent carbon dots for sensitive and selective detection of iron(iii)?
  Ruili Liu,Mengping Gao,Jing Zhang,Zhilian Li,Jinyang Chen,Ping Liu,Dongqing Wu RSC Adv., 2015,5, 24205-24209
• 3. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 4. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 5. Aluminium coordination complexes in copolymerization reactions of carbon dioxide and epoxides
  Nduka Ikpo,Jenna C. Flogeras,Francesca M. Kerton Dalton Trans., 2013,42, 8998-9006

Research Briefing on 3-(tert-Butyldimethylsiloxy)propylmagnesium bromide (0.50 M in THF) and Its Applications in Chemical Biology and Pharmaceutical Research

Recent advancements in chemical biology and pharmaceutical research have highlighted the importance of organomagnesium reagents, particularly 3-(tert-Butyldimethylsiloxy)propylmagnesium bromide (CAS: 158529-76-1), as versatile intermediates in synthetic chemistry. This briefing provides an overview of the latest research developments involving this reagent, focusing on its applications, mechanisms, and potential therapeutic implications.

3-(tert-Butyldimethylsiloxy)propylmagnesium bromide (0.50 M in THF) is a Grignard reagent widely used in organic synthesis for the introduction of the 3-(tert-butyldimethylsiloxy)propyl group. Its stability in tetrahydrofuran (THF) solution makes it a preferred choice for nucleophilic addition reactions, enabling the synthesis of complex molecules with high precision. Recent studies have explored its role in the construction of bioactive compounds, including pharmaceuticals and agrochemicals.

A notable application of this reagent is in the synthesis of silicon-containing organic compounds, which are increasingly relevant in drug discovery due to their enhanced metabolic stability and bioavailability. Researchers have utilized 3-(tert-Butyldimethylsiloxy)propylmagnesium bromide to introduce silicon moieties into drug candidates, improving their pharmacokinetic properties. For instance, a 2023 study demonstrated its efficacy in the synthesis of silicon-based protease inhibitors, showcasing its potential in targeting viral and bacterial enzymes.

In addition to its synthetic utility, recent investigations have focused on the mechanistic aspects of reactions involving this Grignard reagent. Advanced spectroscopic techniques, such as NMR and X-ray crystallography, have been employed to elucidate its reactivity patterns and intermediate structures. These insights are critical for optimizing reaction conditions and minimizing side products, thereby enhancing the efficiency of large-scale pharmaceutical manufacturing.

Furthermore, the reagent's compatibility with other functional groups has been a subject of interest. Studies have shown that 3-(tert-Butyldimethylsiloxy)propylmagnesium bromide can participate in tandem reactions, such as nucleophilic additions followed by cyclizations, to generate heterocyclic scaffolds. These scaffolds are prevalent in many FDA-approved drugs, underscoring the reagent's significance in medicinal chemistry.

Looking ahead, the integration of this reagent into automated and flow chemistry systems is an emerging trend. Researchers are exploring its use in continuous manufacturing processes to achieve higher yields and reproducibility. Such advancements align with the pharmaceutical industry's shift toward sustainable and scalable production methods.

In conclusion, 3-(tert-Butyldimethylsiloxy)propylmagnesium bromide (0.50 M in THF) continues to be a pivotal tool in chemical biology and pharmaceutical research. Its versatility, coupled with ongoing mechanistic and applicative studies, positions it as a key player in the development of next-generation therapeutics. Future research is expected to further expand its utility, particularly in the design of silicon-based drugs and green chemistry initiatives.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)